% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Jakob:303658,
      author       = {D. Jakob and D. Dannehl and H. Endres and L. Jansen$^*$ and
                      S. Hermann$^*$ and A. D. Hartkopf and S. Huwer and L. Jung
                      and O. Thijssen and I. Juhasz-Böss and F. A. Taran},
      title        = {{T}reatment and survival of early non-metastatic breast
                      cancer in men: real world data from a population-based
                      registry.},
      journal      = {Archives of gynecology and obstetrics},
      volume       = {nn},
      issn         = {0003-9128},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2025-01721},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {This study aimed to characterize a cohort of male patients
                      with non-metastatic breast cancer, specifically focusing on
                      tumor characteristics, treatment strategies, and
                      determinants of overall survival.Data for this study were
                      obtained from the Baden-Württemberg Cancer Registry,
                      encompassing male patients diagnosed with breast cancer
                      between 2015 and 2023. A total of 470 patient records were
                      included. We described patient and tumor characteristics
                      using descriptive statistics. Overall survival was analyzed
                      using Kaplan-Meier survival curves and Cox proportional
                      hazards regression models to identify significant
                      determinants.In our cohort of male patients with
                      non-metastatic breast cancer, luminal subtype was the
                      predominant tumor biology, accounting for $90\%$ of cases.
                      HER2-positive tumors were observed in $9\%$ of patients,
                      while triple-negative tumors were rare, with only four cases
                      identified. Regarding tumor staging, $81.7\%$ of patients
                      were diagnosed at T1 or T2 stages. However, a substantial
                      proportion $(48.7\%)$ presented with clinically involved
                      lymph nodes, and $27.1\%$ were diagnosed at UICC stage III.
                      The five-year overall survival rate for the cohort was
                      $73.7\%.$ Treatment analysis revealed that $86\%$ of
                      patients underwent surgical intervention. Mastectomy
                      combined with sentinel lymph node dissection was the most
                      frequent surgical procedure, performed in $50.6\%$ of cases.
                      Adjuvant radiotherapy was administered to $72.8\%$ of
                      patients. Cox regression analysis identified age, nodal
                      status, and surgical intervention as significant
                      determinants of overall survival.},
      keywords     = {Male breast cancer (Other) / Real-world data (Other) /
                      Surgery (Other)},
      cin          = {M110},
      ddc          = {610},
      cid          = {I:(DE-He78)M110-20160331},
      pnm          = {319H - Addenda (POF4-319H)},
      pid          = {G:(DE-HGF)POF4-319H},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40824530},
      doi          = {10.1007/s00404-025-08139-8},
      url          = {https://inrepo02.dkfz.de/record/303658},
}